KR100873059B1 - The use of beta-glucan for treatment and preventing obesity - Google Patents

Abstract

The present invention relates to the use of beta glucan for the prevention of obesity treatment, characterized in that beta glucan exhibits an effect of inhibiting fat accumulation, such as weight loss as well as body fat reduction, blood cholesterol and leptin lowering.

Beta Glucan, Obesity, Diet, Body Fat

Description

The use of beta-glucan for treatment and preventing obesity

The present invention relates to the use of beta glucan to inhibit fat accumulation, and more particularly, to the use of beta glucan produced from microorganisms to effectively inhibit fat accumulation and to reduce the size of fat cells, thereby ultimately effectively reducing weight.

In modern times, obesity has become a social problem due to excessive nutrition and lack of exercise due to changes in living environment. Consumption of animal food per capita increased significantly due to changes in dietary habits, and ingestion of processed foods with high fat content and low dietary fiber content increased due to westernized eating habits and increased opportunities for eating out. This change affects the major causes of death in Korea, and recently, circulatory diseases and cancers are the leading causes of death. In particular, the ratio of chronic degenerative diseases including circulatory diseases is increasing.

Diseases that cause fat accumulation, or obesity, include:                         

First, as the weight increases, the amount of blood required increases and the heart's ability to supply blood becomes unreasonable, causing heart disease, and increasing fat components such as cholesterol and triglycerides in the blood, which causes hyperlipidemia. Cardiovascular diseases such as hypertension, angina pectoris, myocardial infarction, and arteriosclerosis occur.

Second, obese people are three times more likely to develop diabetes than normal weight people. Insulin, which regulates blood sugar, does not work well with fat, resulting in diabetes.

Third, insulin, which has lost its effect due to obesity, increases its secretion amount, and this insulin acts to store excess calories in the form of fat in the liver, and excessive accumulation of fat in the liver leads to poor liver function and fatigue or abdominal discomfort. Symptoms may appear.

Fourth, in obese people, men are more likely to have colon and prostate cancer, and women with endometrial cancer, ovarian cancer, breast cancer and gallbladder cancer.

In addition, obesity causes weight-bearing joints, especially in the lower back and knee joints, causing arthritis. The balance of female hormones in the body is disrupted, causing irregular periods and cycles, and in severe cases, loss of menstruation or infertility. .

Methods for resolving obesity include: eating or fasting, inhibiting absorption of fat or synthesis of body fat, reducing appetite with satiety, and helping to help bowel movement. Dietary fiber is considered a very important factor.

Dietary fiber is a total of indigestible polysaccharides that are not digested in the digestive organs of animals and are contained in grains, embryos, and vegetables.

Dietary fiber shortens the transit time of the ingested high-fat diet and slows the absorption of fat into the body by reducing the adsorption of bile acids and the dissolution of cholesterol and triglyceride digests. In addition, it is known to be effective in preventing digestive diseases such as colorectal cancer by excellent water-absorbing conservatism to make you feel satiety, promote the movement of the intestine and adsorb unnecessary harmful substances in the intestine.

Dietary fiber is water-soluble and non-water-soluble. The water-insoluble dietary fiber is cellulose, hemicellulose, lignin, protofectin, and the water-soluble dietary fiber is pectin, mannan and alginic acid. This dietary fiber is found in vegetables, grains, beans and immature fruits.

Many results have been reported for the use of dietary fiber to prevent fat accumulation and to resolve obesity. US Patent 4892747 describes low calorie foods using water-soluble dietary fiber extracted from grains, US Patent 4892748 describes low calorie diets for animals using methylcellulose gum, US Pat. No. 5,324,526 contains food containing alginin. And beverages, US Pat. No. 5,340,315 to dietary foods including oats, arabic gum, methylcellulose, and US Pat. No. 5,932,561 to dietary foods including chitosan and aloe.

Even in Korea, Korean Patent Laid-Open Publication No. 2001-0103065 discloses a diet composition comprising Garcinia cambogia extract, Hibiscus extract, Caslara sagrada, green tea extract, and the like. Dietary compositions containing chitosan, garcinia cambosinia extracts, fruiting fruit extracts, extracts from the wild gland, and the like have been reported.

Accordingly, it is an object of the present invention to provide a use of beta glucan to inhibit fat accumulation by searching for substances that can inhibit and prevent the accumulation of fat and reduce the size of fat cells.

In order to achieve the above object, the present invention was confirmed to include beta glucan in the diet to reduce body fat and reduce the size of fat cells.

The present invention relates to the use of beta glucan to inhibit fat accumulation by including beta glucan in the diet.

In addition, the present invention relates to the use of beta glucan to inhibit fat accumulation, characterized in that by reducing the size of fat cells by including beta glucan in the diet.

Furthermore, the present invention is characterized in that the beta glucan is produced by the fermentation of microorganisms.

delete

In the present invention, beta glucan having a fat accumulation inhibitory effect may be included in a general meal or diet, or may be in the form of a separate dietary supplement. As a dietary supplement form, it can be prepared in various forms, such as a powder mixture, or capsules, tablets, beverages, which are commonly used. In addition, even when beta glucan is added directly to a beverage or food can be expected to inhibit fat accumulation.

Beta-glucans are produced in various forms from yeast, mushrooms, and cereals. Beta-glucan used in the present invention is limited to those produced by microbial fermentation such as Agrobacterium, in the embodiment of the present invention using sugar as a carbon source from Agrobacterium, ammonium chloride as a nitrogen source, and other Betaglucan was produced by culturing in fermentation broth containing inorganic matter.

After fermentation is complete, beta glucan is in an insoluble state. Beta-glucan is insoluble in neutral solution, so to separate the beta-glucans from the fermentation broth with cells, the culture solution is basified (pH 10 or more) to dissolve the beta-glucans and then the cells are removed by centrifugation or filter.

Beta glucan is precipitated by contacting this solution with a water-soluble organic solvent or neutralizing the solution, followed by centrifugation and drying to obtain a purified powder.

In the present invention, three weeks-old Sprague-Dawley species male rats were fed as a high-fat diet for 6 weeks using experimental rats, and induction of obesity for 4 weeks was added 0.1% to 5% of beta glucan in the diet. The weight loss effect by beta glucan is confirmed by measuring diet and weight gain during 4 weeks. If the beta glucan is less than 0.1% by weight, the effect is insignificant, and if it is 5% by weight or more, there is no significant difference in the effect compared to the amount of beta glucan is not economical.

In an embodiment of the present invention, the interscapular brown adipose tissue, the visceral fat, the peritoneal fat, and the epididymal fat are separated from the group to which the beta glucan is added and the group to which the beta glucan is added. By measuring the weight and the size of the beta glucan was examined the fat reduction effect.

In addition, in the embodiment of the present invention to determine the effect of beta glucan on cholesterol levels by measuring the amount of cholesterol by separating the serum in the blood, beta glucan lipid and the change in the concentration of leptin (leptin) and insulin (insulin) in the blood The effects on energy metabolism were examined.

Hereinafter, the configuration of the present invention will be described in detail with reference to the following examples. However, the scope of the present invention is not limited by the description range of an Example.

Example 1 Weight Loss Effect by Beta Glucan

The experimental animals were purchased from 3 weeks old Sprague-Dawley male rats and divided into two groups: normal diet and high-fat diet.

The normal diet group was AIN-76A diet # 100000 (Dyets Inc., Bethlehem, PA, USA), which supplied 11.7% of the total calories to fat, and the high-fat diet group used bee tallow as a fat source. -76 High fat diet # 100496 (Dyets Inc., Bethlehem, PA, USA) was fed 40% of the total calories to fat.

The experimental animals were fed a normal diet and a high fat diet for 6 weeks from 4 weeks to 10 weeks of age, and a diet containing 1% and 5% of glucan in the high fat diet for 10 weeks to 4 weeks, respectively. Was observed.

The test animals were separated and bred one by one, and water and diet were supplied without restriction. Dietary intake and body weight were measured twice a week during the experiment. The food efficiency ratio (FER) was calculated by dividing the weight gain during the experiment period by the dietary intake during the experiment period from the supply date of the experiment to the sacrifice day. Table 1 shows the weight change, weight gain, and daily weight gain for each experimental group for 4 weeks.

 Daily weight gain (A, g / day)  Daily Dietary Intake (B, g / day)  Dietary Efficiency (A / B * 100)  Normal diet  2.36  28.99  8.14  High fat diet  2.66  21.98  12.10  Beta Glucan 1%  2.06  25.63  8.04  Beta Glucan 5%  2.06  23.88  8.63

When more than 1% of beta glucan was added to the high-fat diet group, the weight gain was reduced by more than 20% compared to the high-fat diet group, and the weight gain was less than that of the normal diet. In particular, when looking at the dietary efficiency (weight gain / dietary intake), the amount of food consumed during the whole period was lower in the high fat group than in the normal group, but the weight gained due to the high calorie intake of fat, and the beta glucan was administered (1% or more). The weight gain was similar to that of the normal diet even though high-fat diet was consumed.

Example 2 Effect of Decrease of Adipocyte Weight and Size by Beta Glucan

At the time of 4, 6, 8, 10, or 16 weeks of age, four animals (4, 6, 8 weeks) or 6 (10, 16 weeks) of each group were randomly extracted and sacrificed for blood and organs. Was taken. Interscapular brown adipose tissue, visceral fat, peritoneal fat and epididymal fat were measured and weighed. Table 2 shows the fat weight of each experimental group (100). fat weight per g body weight).

 Visceral fat (g / 100 weight)  Peritoneal Fat (g / 100 Body Weight)  Epididymal fat (g / 100 body weight)  % Of total fat  Normal diet  1.3  2.05  1.2  66  High fat diet  2.4  2.7  1.8  100  Beta Glucan 1%  1.6  1.1  1.35  59  Beta Glucan 5%  1.4  1.35  1.3  59

Where the difference in weight comes from the weight of the fat was found. The addition of beta-glucan to the high-fat diet showed a difference of more than 40% in fat, which was close to that of the normal diet, especially in the case of peritoneal fat, compared to the normal diet group.

The average size of adipocytes was cut about 30 times with extracted epididymal adipose tissue with scissors, followed by a medium containing 4% (wt / vol) albumin and 1.5 mg / ml collagenase (Sigma, USA). After homogenization at 37 ° C. for 60 minutes in (Gibco BRL), the diameter of approximately 30 cells was measured using a microscope and averaged.

 Normal diet  High fat diet  Beta Glucan 1%  Beta Glucan 5%  Fat cell size (μm)  10.73 ± 3.03  18.72 ± 4.11  9.74 ± 0.49  8.46 ± 1.15

As shown in Table 3, the size of the fat cells was 1.7 times larger in the high fat diet group than the normal diet group, and the size of the fat cells was increased by the high fat intake.

In the case of glucan diet, adipocyte size was lower than normal diet group.

Example 3 Changes in Blood Cholesterol and Triglyceride Contents by Beta Glucan

Blood was collected by puncturing the heart at sacrifice and centrifuged at 3000 rpm for 15 minutes to obtain serum, and these samples were stored at -70 ° C until analysis.

The total fat content of serum was measured by colorimetric method by Frings method (Frings et al., 1970), and the content of cholesterol and triglyceride was measured by enzyme colorimetric method using kit (Sigma Chemical Co. (St. Louis, MO)).

HDL cholesterol was precipitated LDL and VLDL using the precipitation reagent, dextran sulfate MgCl ₂ , and the cholesterol content of the supernatant was colorimetrically determined using a kit (Sigma, USA).

 Total cholesterol (mg / dl)  HDL Cholesterol (mg / dl)  Triglycerides (mg / dl)  Normal diet  60.71  46.63  63.00  High fat diet  73.10  44.60  82.50  Beta Glucan 1%  66.00  57.00  60.33  Beta Glucan 5%  63.00  56.67  56.80

Serum total cholesterol was not different among the experimental groups, but HDL cholesterol, which lowers the concentration of blood cholesterol, was significantly increased in the glucan diet group than the high fat control group. Serum triglycerides were significantly increased in the high fat control group compared to the normal control group, but significantly decreased in the glucan-supplied group, with 73% and 69% levels of the 1% glucan group and the 5% group added, respectively. Lower values than the normal control.

Example 4 Changes in Blood Leptin Content by Beta Glucan

Leptin content in the serum was measured for radioimmunity using Linco leptin assay kit (Linco research Immunoassay, St. Charles, MO). Serum leptin content was lower in the glucan group than in the high fat control group, and was reduced to 25% of the high fat control group by the 5% diet and decreased to almost the normal control level (Table 5).

Leptin acts as an inhibitory mechanism for obesity, and leptin production increases when energy is excessively accumulated, so leptin levels can be used as an indicator of obesity. In this regard, the reduction of leptin in the blood by glucan diet may be an indicator of glucan's improvement in obesity.

Leptin (mg / ml)                                               Normal diet  1.97  High fat diet  5.73  Beta Glucan 1%  1.23  Beta Glucan 5%  1.45

The inclusion of beta glucan in the diet reduced fat accumulation, especially abdominal fat, which was more than 40% lower than the normal diet, which was especially effective for abdominal obesity.

In addition, beta glucan has an anti-obesity effect by inhibiting body fat formation and accumulation by affecting lipid and energy metabolism improvement.                     

By using the effect of reducing the fat accumulation of beta glucan shows that it can be used for the purpose of preventing or treating obesity.

Claims (6)

Agrobacterium derived betaglucan, used to inhibit fat accumulation and reduce the size of fat cells. delete delete A diet containing Agrobacterium-derived betaglucan, used to inhibit fat accumulation and reduce the size of fat cells. delete delete